Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products

Description

NHS Supply Chain seeks to establish a Framework Agreement for the supply of Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products. This includes but not limited to tethered and patch insulin pumps, continuous glucose monitoring devices, products that contribute to the functionality of hybrid closed loop insulin delivery systems, and consumables. Precise quantities are unknown. It is anticipated in the first year that spend will be approximately £ 240,000,000 - £267,000,000 GBP (Excluding VAT), however this is approximate only and may vary depending on requirements of bodies purchasing under the Framework. Estimated total value over the 4 year agreement is approximately £960,000,000 to £1,067,000,000 Excluding VAT. Please note it is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-yearimplementationstrategy/ Lot Lot 1: Insulin Pumps This Lot aims to offer Patch Insulin Pumps and Tethered Insulin Pumps and associated consumables or accessories. Lot Lot 2: Continuous Glucose Monitors This Lot aims to offer Continuous Glucose Monitors and associated consumables or accessories. Lot Lot 3: Software and Diabetes Management Systems Applications and/or software that contributes to the functionality of a closed loop insulin delivery system. Products that connect with blood glucose sensors and insulin pumps to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with diabetes.